Corium is a commercial-stage biopharmaceutical company leading the development of new transdermal healthcare products that provide clinicians with important treatment options for patients and their families.

Read more

 
Aug 3, 2017
Corium Reports Recent Corporate Highlights and Financial Results for Third Quarter Fiscal 2017
MENLO PARK, Calif., Aug. 03, 2017 (GLOBE NEWSWIRE) — Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results for the third fiscal quarter and the nine months ended June 30, 20…


Jul 27, 2017
Corium to Report Third Quarter Fiscal 2017 Financial Results on Thursday, August 3, 2017
MENLO PARK, Calif., July 27, 2017 (GLOBE NEWSWIRE) — Corium International, Inc. (NASDAQ:CORI) today announced that it will report financial results for the third quarter ended June 30, 2017 on Thursday, August 3, 2017 after the close of the U.S. financial markets. Corium will host a conference call and live audio webcast at 5:00 p.m. Eastern ti…

OUR LEAD PRODUCT

CorplexTM Donepezil

A once-weekly treatment for Alzheimer’s disease, our lead product is a transdermal formulation of donepezil, the active ingredient in Aricept®, which is one of the most commonly prescribed treatments for the care of patients with Alzheimer’s disease. We have demonstrated sustained and controlled delivery of donepezil over a one-week period, with a pharmacokinetic (PK) profile comparable to oral Aricept taken daily for seven days. Learn more

circle_couple2